Pacific Biosciences of California, Inc. [NASDAQ:PACB]: Analyst Rating and Earnings
Experts stock market traders frequently make a point to check what top Wall Street analysts say regarding a potential buy. Regarding Pacific Biosciences of California, Inc. [PACB] currently, the latest Wall Street ratings we can see is from the fiscal quarter that’s going to end in December. On average, stock market experts give PACB an Hold rating. Its stock price has been found in the range of 2.43 to 7.84. This is compared to its latest closing price of $7.34.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Pacific Biosciences of California, Inc. [PACB] is sitting at 3.00. This is compared to 1 month ago, when its average rating was 3.00.
For the quarter ending in Mar-19 Pacific Biosciences of California, Inc. [PACB] generated $0.02 billion in sales. That’s 24.11% lower than the average estimate of $0.02 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.
Stay on the lookout for the next publication of this organization’s financial results for the quarter, which will be made public on Thu 1 Aug (In 76 Days).
Fundamental Analysis of Pacific Biosciences of California, Inc. [PACB]
Now let’s turn to look at profitability: with a current Operating Margin for Pacific Biosciences of California, Inc. [PACB] sitting at -128.44 and its Gross Margin at +31.92.
This company’s Return on Total Capital is -88.41, and its Return on Invested Capital has reached -78.40%. Its Return on Equity is -102.48, and its Return on Assets is -65.25. These metrics suggest that this Pacific Biosciences of California, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Pacific Biosciences of California, Inc. [PACB] has generated a Total Debt to Total Equity ratio of 12.85. Similarly, its Total Debt to Total Capital is 11.39, while its Total Debt to Total Assets stands at 8.61. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 12.85, and its Long-Term Debt to Total Capital is 11.39. This company has a healthy balance between its debt and its current holdings, suggesting it is a reliable investment due to its ability to leverage debt in an efficient way.
What about valuation? This company’s Enterprise Value to EBITDA is -11.13. The Enterprise Value to Sales for this firm is now 13.79, and its Total Debt to Enterprise Value stands at 0.02. Pacific Biosciences of California, Inc. [PACB] has a Price to Book Ratio of 9.75.
Shifting the focus to workforce efficiency, Pacific Biosciences of California, Inc. [PACB] earns $196,075 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 7.14 and its Total Asset Turnover is 0.50. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 4.23 and its Current Ratio is 4.90. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Pacific Biosciences of California, Inc. [PACB] has 150.82M shares outstanding, amounting to a total market cap of $1.11B. Its stock price has been found in the range of 2.43 to 7.84. At its current price, it has moved by -6.51% from its 52-week high, and it has moved 201.03% from its 52-week low.
This stock’s Beta value is currently 2.32, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 46.61. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Pacific Biosciences of California, Inc. [PACB] a Reliable Buy?
Shares of Pacific Biosciences of California, Inc. [PACB], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.